The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

EDi001-A-5

AST23-2KO-II8B

Gene-edited iPSC line

Not released.
We are currently making some changes to how EBiSC operates and because of this there is a short period of time where orders cannot be placed.

If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
The cell line is not released.

General#

Cell Line

hPSCreg name EDi001-A-5
Alternative name(s)
AST23-2KO-II8B
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A
(AST22, AST23, SAMEA3319992)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi024-A
(SFC831-03-01)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-C
(SFC831-03-05)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-C
(SFC828-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-B
(SFC829-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi008-B
(G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi083-B
(SFC830-04-08)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-A
(SFC828-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-B
(SFC828-03-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-B
(SFC831-03-03)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-A
(SFC829-03-02)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-C
(SFC829-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi083-A
(SFC830-04-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi001-A
(MK071-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-B
(MK071-3)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi007-A
(MK002-4)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi008-B
(MK144-7)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi004-A
(SFC832-03-19)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi084-A
(SFC871-03-12)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi084-C
(SFC871-03-09)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi002-B
(MK082-30)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi003-A
(MK088-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi267-A
(SFC027-03-02)
Donor diseases:
Parkinson disease
STBCi025-C
(SFC834-03-10)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi320-A
(SFC031-03-03)
Donor diseases:
Parkinson disease
STBCi005-A
(SFC833-03-01)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-A
(SFC855-03-06)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi085-A
(SFC866-03-06)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi088-A
(SFC872-03-05)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
ESi002-A
(SP08#1)
Donor diseases:
Parkinson disease
ESi006-A
(SP13#4)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi004-B
(SFC832-03-06)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi004-C
(SFC832-03-07)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi001-C
(MK071-5)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-D
(MK071-6)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi266-A
(SFC072-03-06)
Donor diseases:
Parkinson disease
STBCi278-A
(SFC245-03-08)
Donor diseases:
Parkinson disease
STBCi280-A
(SFC066-03-01)
Donor diseases:
Parkinson disease
STBCi283-A
(SFC073-03-08)
Donor diseases:
Parkinson disease
STBCi292-A
(SFC139-03-06)
Donor diseases:
Parkinson disease
STBCi293-A
(SFC843-03-09)
Donor diseases:
Parkinson disease
STBCi297-A
(SFC061-03-07)
Donor diseases:
Parkinson disease
STBCi303-A
(SFC071-03-09)
Donor diseases:
Parkinson disease
STBCi304-A
(SFC074-03-03)
Donor diseases:
Parkinson disease
STBCi307-A
(SFC088-03-05)
Donor diseases:
Parkinson disease
STBCi308-A
(SFC249-03-06)
Donor diseases:
Parkinson disease

Provider

Depositor University of Edinburgh (ED)
Distributors
EBiSC

External Databases

hPSCreg EDi001-A-5
BioSamples SAMEA7111748
Cellosaurus CVCL_D0VC
Wikidata Q123031227

General Information

Publications View all related publications on hPSCreg (1)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
This is a PD line, with the control being EDi002-A lines and CRISPR/Cas9-corrected EDi001-A-1, EDi001-A-2, EDi001-A-3 and EDi001-A-4
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans
Genetic variants
SNCA (target)
4q22.1
Heterozygous
The donor carries a triplication of the alpha-synuclein gene, resulting in 4 copies of SNCA. The copies of SNCA are situated in a heterozygous triplication configuration. See Figure 1 of Petrucci, 2015 for a graphic representation of the heterozygous triplication.
Family history Strong family history of Parkinson’s disease due to autosomal dominant inheritance of SNCA triplication
Is the medical history available upon request? Y Mov Disord. 2011 Sep;26(11):2134-6. doi: 10.1002/mds.23776

Donor Relations

Other cell lines of this donor
All cell lines of this donor's relatives
Has daughter:

External Databases (Donor)

BioSamples SAMEA3319991

hIPSC Derivation#

General

The source cell information can be found in the parental cell line EDi001-A.

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
Unknown
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Yes

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Laminin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: StemMACS™ iPS-Brew XF
Main protein source:
Serum concentration: %

Characterisation#

No characterisation data could be found for this subclone. Please open parental cell line EDi001-A .

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No gross chromosomal abnormalities
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans
Genetic modifications
SNCA (target)
Gene knock-out
4q22.1
The SNCA triplication has been gene edited to become *putatively* normal. CRISPR/Cas was employed to create a mutation in Exon2, disrupting the ATG start site and some sequence 5' to the coding start of SNCA. PCR amplicons of the CRISPR site were cloned using the TOPO cloning technique. Sequencing of 8 TOPO clones detected 2 deletions, both of which disrupt the first ATG start site. This indicates 2 alleles were putatively knocked out, and 2 alleles remain. Additional comment: there are two additional ATG sites located immediately downstream of the normal ATG start site, one of which is in-frame (9 bases) to the initial ATG. It is possible that inactivation of the first ATG start site might not be completely sufficient to prevent translation from the second downstream ATG, which is in-frame to the first.
CRISPR-associated (CRISPR/Cas) System